pharma · NATCOPHARM

Natco Pharma

Natco Pharma: PE above historical average. ROTATIONAL regime.

Price

₹877.5

Price 2026-08-20

5 day

-2.68%

Short-term move

1 month

-8.77%

Medium-term

Regime

ROTATIONAL

68% confidence

Market cap

₹17.6k Cr

neutral sector flow

Market Intelligence Analyst

Understand today's market in about 2 minutes.

How does today's ROTATIONAL regime affect Natco Pharma (NATCOPHARM) in the pharma sector?

Ask about this stock

Price chart

897

-12.85% over period

2025-07-18759 – ₹1,2052026-08-18

About Natco Pharma

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Drug Manufacturers - Specialty & GenericHyderabad, IndiaWebsite →

At a Glance

ValuationPE 12.4 (57%ile of 7 quarterly points (limited history), range 7-27). Trading near median.
Sector Positionpharma sector. Flow: neutral. is not among current leaders. Regime: ROTATIONAL (68%).
Historical ContextRSI oversold bounces for this stock succeeded only 0% of the time (avg -10.5% over 14 days) — not a reliable pattern.
Revenue TrendRevenue declining at -3960.0% YoY. Revenue declining — -3960.0% YoY

RSI pattern warning

RSI oversold bounces for this stock succeeded only 0% of the time (avg -10.5% over 14 days) — not a reliable pattern.

52-week position

Trading at 71.5% of 52-week high

52W low ₹78952W high ₹1,226.8

Technicals

RSI 14

39

Trend

downtrend

50 DMA

Below

200 DMA

Below

Key metrics

P/E ratio

12.4

57th pct · 7 quarterly points (limited history)

P/B

1.9

ROE

16.9%

Moderate profitability — 16.9% ROE

Market cap

₹17.6k Cr

Revenue growth

-3960.0% YoY

Promoter

51.0%

52-week range

₹789 – ₹1,226.8

71.5% of high

RSI (14)

39.0

downtrend

vs 50 DMA

Below

DMA ₹920.55

Coverage

100/100

HIGH

Quick Take

Natco Pharma: PE above historical average. ROTATIONAL regime.

Peer comparison

StockPrice5DP/EROERev growthMcap
DIVISLAB

Divi's Laboratories

₹8,570+0.8%7016.2%950%₹1.8L Cr
CIPLA

Cipla

₹1,438-1.4%30.211.7%-210%₹1.2L Cr
DRREDDY

Dr. Reddy's Laboratories

₹1,180-2.2%26.511.8%-1160%₹1.1L Cr
AUROPHARMA

Aurobindo Pharma

₹1,608-3.3%26.39.9%560%₹91.1k Cr
ALKEM

Alkem Laboratories

₹5,400-0.9%29.417.6%1460%₹67.8k Cr
BIOCON

Biocon

₹412.5-1.8%145.31.1%230%₹66.3k Cr
GLENMARK

Glenmark Pharmaceuticals

₹2,332.9+0.6%4714.1%1430%₹63.9k Cr
GLAND

Gland Pharma

₹2,820-5.0%40.910.5%2230%₹42.1k Cr
NATCOPHARM

Natco Pharma

₹877.5-7.6%12.416.9%-3960%₹17.6k Cr

Tensions to watch

Promoter holding at 51.0% — neither distress selling nor aggressive buying

No strong insider signal. Watch for changes in promoter stake as a leading indicator.

Key Watchpoints

🟢

Breaks above ₹921 (+5%)

Trend reversal confirmation

🔴

Breaks below ₹834 (-5%)

Further downside risk

🟡

PE reverts to median of 11.6 (7 quarterly points (limited history))

Valuation normalization

🟢

Pharma sector entering leadership

Sector rotation signal

Facts

P/E Ratio
12.4MODERATE
P/B Ratio
1.9HIGH
ROE
1685.0%HIGH
Market Cap
₹1762709.8L CrHIGH
From 52W High
72% of high
Promoter Holding
51.0%MODERATE
Institutional
12.4%
Sector Peers
10
FinGenieFinGenie

Understand today's market in about 2 minutes. Ask your analyst